8-K: Inogen Announces Preliminary Q4 and Full Year 2024 Revenue, Exceeding Expectations

Inogen reports preliminary unaudited revenue for Q4 and full year 2024, exceeding previous guidance with strong business-to-business growth.

Summary

• Inogen, Inc. announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2024.
• The company estimates Q4 2024 revenue to be in the range of $79.0 million to $80.0 million, representing a 4% to 5% year-over-year increase.
• Full year 2024 revenue is estimated to be between $334.5 million and $335.5 million, a 6% increase year-over-year.
• This exceeds the previously announced full year 2024 guidance range of $329 million to $331 million.
• The company attributes the performance to strong double-digit growth in business-to-business revenue.
• Inogen is working to stabilize direct-to-consumer revenue through initiatives aimed at enhancing overall profitability.
• The company launched Rove 4 and received FDA clearance for the SIMEOX 200 device during the quarter.
• Inogen will report its official fourth quarter and full year 2024 financial results on February 25, 2025.
• A conference call will be held on the same day to discuss the results.

Sentiment

Score: 8

Explanation: The sentiment is positive due to exceeding revenue guidance, strong B2B growth, and new product launches. However, the need to stabilize direct-to-consumer revenue and the presence of general risk factors temper the enthusiasm slightly.

Positives

• Inogen achieved a return to revenue growth in 2024.
• The company improved profitability and practiced disciplined cost management.
• Business-to-business revenue experienced strong double-digit growth.
• Inogen exceeded its previously announced full year 2024 revenue guidance.
• The launch of Rove 4 and FDA clearance for SIMEOX 200 diversifies the product offerings.

Negatives

• The company is working to stabilize direct-to-consumer revenue, indicating potential challenges in that segment.

Risks

• The forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from anticipated results.
• These risks include market acceptance of products, competition, supply chain interruptions, and unanticipated cost increases.

Future Outlook

Management is confident in their team's ability to continue delivering on commitments and providing leading devices for patients with respiratory diseases in 2025 and beyond.

Management Comments

• Kevin Smith, President and Chief Executive Officer of Inogen, stated that 2024 was a very successful year for Inogen, driving a return to revenue growth, improved profitability, and disciplined cost management.
• He also highlighted the launch of Rove 4 and FDA clearance for the SIMEOX 200 device as achievements in the quarter.

Industry Context

Inogen operates in the medical technology industry, specifically focusing on respiratory products for homecare. The announcement highlights the company's efforts to innovate and expand its product offerings, which is crucial for maintaining competitiveness in this market.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Inogen's specific market share and competitive landscape.
• However, companies like ResMed and Philips Healthcare are major players in the respiratory care market.
• Comparing Inogen's growth rate and profitability to these companies' results would provide a better understanding of its relative performance.
• For example, if ResMed is growing at 10% annually in its respiratory segment, Inogen's 6% growth might be seen as lagging, despite exceeding its own guidance.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and exceeding guidance.
• Patients may benefit from the launch of new and improved respiratory products.
• Employees may experience increased job security and potential for career advancement due to the company's growth.

Next Steps

• Inogen will report its official fourth quarter and full year 2024 financial results on February 25, 2025.
• Inogen management will host a conference call on February 25, 2025, to discuss the results.

Key Dates